Journal profile · Hematology
Blood Cells Molecules and Diseases
ISSN 1079-9796 · eISSN 1096-0961 · Academic Press Inc. · UNITED STATES · Bimonthly · Founded 1995
Blood Cells Molecules and Diseases: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2.13; hybrid open access; APC about USD 4,030; median 55 days to acceptance (62 articles, last 24 months); community-reported acceptance: fairly easy; 36 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Blood Cells Molecules and Diseases is published by Academic Press Inc. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Hemoglobinopathies and Related Disorders, Iron Metabolism and Disorders and Erythrocyte Function and Pathophysiology, together about 38.4% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Blood Cells, Molecules, and Diseases (BCMD) is interested in basic, translational, and clinical Hematology research focusing on the biology of blood cells and the pathophysiology of blood disorders, with a specific interest in non-malignant conditions.BCMD will consider studies on hematological malignancies when secondary to inherited or acquired bone marrow failure or disorders of the immune system.Research Areas include:Erythropoiesis, Erythrocyte Biology, Hemoglobin and its disordersMyelopoiesis, myeloid cells and disorders of the myeloid lineage (incl. myeloproliferative disorders)Megakaryopoiesis and platelet disordersHemostasis & Thrombosis and disorders of coagulationTransfusion medicine and the study of therapeutic blood products (including novel biotechnologies related to transfusion products)Bone marrow failure (severe aplastic anemia, myelodysplasia, etc.)Immunodeficiency and dysregulation of the immune systemAuto-immune disorders relating to blood
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editor-in-chief Lionel BlancPublisher website
Editorial board by country: none in mainland China; most named United States 27, France 6, Switzerland 5, United Kingdom 2, Italy 2 (45 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Hemoglobinopathies and Related DisordersMedicine17.8%
- Iron Metabolism and DisordersMedicine11.6%
- Erythrocyte Function and PathophysiologyMedicine9.1%
- Lysosomal Storage Disorders ResearchMedicine5%
- Blood groups and transfusionMedicine4.6%
- Acute Myeloid Leukemia ResearchMedicine4.5%
- Trace Elements in HealthNursing3.9%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Hematology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.13LetPub ·
- Impact factor (publisher)
- 2.1Publisher website ·
- CiteScore 2026-06
- 3.7LetPub ·
- CiteScore (publisher)
- 3.7Publisher website ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.86LetPub ·
- h-index
- 82LetPub ·
- h-index
- 114OpenAlex ·
- i10-index
- 1,711OpenAlex ·
- 2-year mean citedness
- 1.97OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 19.15%LetPub ·
Volume
- Articles per year
- 24LetPub ·
Articles by year OpenAlex count · 3,076 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 36 | 6 | 6 |
| 2025 | 36 | 11 | 38 |
| 2024 | 49 | 24 | 194 |
| 2023 | 43 | 14 | 266 |
| 2022 | 40 | 10 | 200 |
| 2021 | 67 | 28 | 597 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
55 daysMedian, submission to acceptance · P25–P75 31 days – 88 days
- Acceptance to online
- median 3 days (62 articles)
- Submission to online
- median 59 days
- Sample
- 62 articles with submission and acceptance dates (77 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 22 daysPublisher website ·
- Submission to acceptance
- 56 daysPublisher website ·
- Acceptance to publication
- 4 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,030 / EUR 3,770 / GBP 3,230 / JPY 499,840 | — | — | |
| Publisher website | USD 3,960 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 10,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
Article types accepted8, with length limits
- commentaryFull length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manusc…main text ≤ 1,000 words
- correspondencee subject to the normal review process. Correspondence Letters must be limited to fewer than 1000 words, not inclusive of figures and tables. References must no…main text ≤ 1,000 words
- full length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscripts will undergo …Length not stated
- letterFull length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manusc…Length not stated
- letters to the editorFull length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manusc…main text ≤ 1,000 words
- original researchFull length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manusc…Length not stated
- reviewFull length articleThese are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manusc…Length not stated
- reviewsThe Review should be a comprehensive appraisal of research in a field of current interest. Authors wishing to contribute a review paper should contact one of co…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Academic Press Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1995
- ISSN
- 1079-9796
- Electronic ISSN
- 1096-0961
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Blood Cells Molecules and Diseases
What CAS zone is Blood Cells Molecules and Diseases in?
In the 2025 upgraded edition of the CAS Journal Ranking, Blood Cells Molecules and Diseases is in Zone 4 of Medicine, and in Zone 4 of the minor category Hematology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Blood Cells Molecules and Diseases?
The latest impact factor listed by LetPub is 2.13; CiteScore 3.7, h-index 114.
How long does peer review take at Blood Cells Molecules and Diseases?
Based on the dates recorded on 62 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 55 days (interquartile range 31–88 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Blood Cells Molecules and Diseases?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 10,000 words; Reference style: Numbered, in order of citation; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Blood Cells Molecules and Diseases based?
Of the 45 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (27), France (6) and Switzerland (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Blood Cells Molecules and Diseases?
According to LetPub and DOAJ records, Blood Cells Molecules and Diseases is indexed in SCIE and Scopus.
Is Blood Cells Molecules and Diseases open access, and what is the APC?
Blood Cells Molecules and Diseases is a hybrid journal. For open-access publication: APC about USD 4,030.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .